Martha Q. Lacy, MD | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Healthcare Professionals
Martha Q. Lacy, MD

Martha Q. Lacy, MD

Healthcare Professional
Consultant
Division of Hematology
Mayo Clinic
200 First St. SW
Rochester, Minnesota, United States

Martha Q. Lacy is a Hematologist at Mayo Clinic, Rochester, Minnesota. She completed her MD from University of Colorado Medical Center and post-doctorate in Hematology/Oncology from Mayo Graduate School of Medicine, Mayo Clinic College of Medicine.

Dr. Lacy has been awarded as Woman of the year in 2015 by Leukemia and Lymphoma Society. She is primarily interested in myeloma, amyloidosis, Waldenstrom’s macroglobulinemia and other dysproteinemias and stem cell transplantation of these diseases.

As a member of Mayo Clinic’s myeloma, amyloidosis, dysproteinemia group, Martha Q. Lacy conducts research in developing new therapeutics for the treatment of plasma cell disorders.

Dr. Lacy’s clinical research centers on immunotherapy, stem cell transplant and novel agents to optimize treatment for multiple myeloma, amyloidosis, Waldenstrom’s macroglobulinemia and monoclonal gammopathy. She performs clinical trials and collaborates with scientists on translational research to improve outcomes for patients with these disorders.

 

Representative Publications:

Natural history of multiple myeloma with de novo del(17p)

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma 

view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close